3D Microtissue Drug Screening via Pharmacokinetic Timing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug screening methods in the pharmaceutical industry are inefficient, leading to a high failure rate of cancer drugs in clinical trials due to inaccurate pre-clinical test results. These methods fail to accurately mimic the in vivo situation, particularly in terms of pharmacokinetic properties and drug exposure times.
Innovation Solution
The development of a method that uses 3D microtissue cultures derived from patient-specific tissue samples to screen drugs or drug combinations. This method takes into account the pharmacokinetic parameters of each drug, such as half-life (t½), maximum concentration (Cmax), and time to maximum concentration (Tmax), to simulate the in vivo drug exposure scenario. Drugs are added to the microtissue cultures at specific time points based on their t½ values, allowing for a more accurate prediction of drug efficacy and adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional high throughput screening methods are used to test drugs in cell cultures, then the screening process is efficient and can be automated, but the results do not accurately predict in vivo drug responses leading to high clinical trial failure rates
Solution Approach 1:
The patent transitions from conventional 2D cell cultures to 3D microtissue cultures that better mimic in vivo tissue architecture and cellular interactions. This dimensional change enables more accurate prediction of drug responses while maintaining screening efficiency through automated handling of microtissue samples.
Solution Approach 2:
The patent introduces pharmacokinetic parameters (half-life, maximum concentration, time to maximum concentration) to control drug exposure in microtissue cultures. By varying these parameters to match in vivo conditions, the method achieves both accurate prediction of drug responses and efficient screening through systematic parameter optimization.
2Ease of operation
If all drugs are applied to cells at the same time in cell culture tests, then the testing process is simple and controllable, but it does not reflect the pharmacokinetic situation in vivo where drugs reach peak concentration at different times
Solution Approach 1:
The patent performs preliminary determination of pharmacokinetic parameters (half-life, maximum concentration, time to maximum concentration) for each drug before applying them to microtissue cultures. This preliminary action enables subsequent controlled application of drugs at different times to match in vivo conditions, maintaining both ease of operation and physiologic relevance.
Solution Approach 2:
The patent implements dynamic drug application protocols where drugs are added to microtissue cultures at different time points based on their pharmacokinetic parameters. This dynamic approach reflects in vivo pharmacokinetic situations while remaining controllable through automated timing and dosage control systems.
3Measurement precision
If 3D microtissue cultures are used to improve physiologic relevance of drug testing, then the predictability of in vivo drug responses is enhanced, but the complexity of managing multiple drugs with different exposure times increases
Solution Approach 1:
The patent segments the testing process into distinct phases based on pharmacokinetic parameters: preliminary parameter determination, controlled drug application at different time points, and systematic observation of effects. This segmentation manages the complexity of multiple drugs with different exposure times while maintaining high predictability of in vivo responses.
Solution Approach 2:
The patent incorporates systematic observation and recording of drug effects at different time points, creating a feedback loop that refines the understanding of drug-microtissue interactions. This feedback mechanism enables accurate prediction of in vivo responses while managing complexity through data-driven optimization of testing protocols.
Data Source
AI summary
The present invention relates to improved methods and systems to analyze physiological effects as a response of cells as obtained to the exposure of a drug compound or combinations thereof. The methods of the present invention offer the particular advantage of providing more relevant results with respect to the in vivo situation, are time-and cost effective, and suitable for automatization.